ReviewInternational journal of chronic obstructive pulmonary disease2006
The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD.
Review in International journal of chronic obstructive pulmonary disease, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Expiratory Muscle Strength, Peak Oxygen Consumption and Hyperinflation Predicts Severe Exacerbation in Chronic Obstructive Pulmonary Disease Patients.Thoracic research and practice · 2026Article
- Prednisone-hydrogen sulfide releasing hybrid shows improved therapeutic profile in asthma.Frontiers in pharmacology · 2023Article
- Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting βJournal of clinical pharmacology · 2016Observational
- Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol.British journal of pharmacology · 2012Article
- The effects of extracellular matrix proteins on neutrophil-endothelial interaction--a roadway to multiple therapeutic opportunities.The Yale journal of biology and medicine · 2012Review
- Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.International journal of chronic obstructive pulmonary disease · 2012Article
- Article
- The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.International journal of chronic obstructive pulmonary disease · 2010Review
- Do symptoms predict COPD in smokers?Chest · 2010Article
- Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety.International journal of chronic obstructive pulmonary disease · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute exacerbations of COPD can complicate the course of the disease in patients with severe airway obstruction. Reduction of exacerbations is an important clinical outcome in evaluating new therapies in COPD. Combination therapies with long-acting beta-agonists and inhaled corticosteroids have now been approved for use. Three 1-year randomized clinical trials, which studied the effect of combining a long-acting beta2-agonist with an inhaled corticosteroid in COPD, documented that exacerbation frequency was lower with therapy than placebo. Combination therapy had a similar effect to its monocomponents in the trial evaluating salmeterol/fluticasone combination. However, when patients with more severe COPD were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rates compared with the use of a long-acting beta2-agonist alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.